Tafolecimab

DRUG9 trials

Conditions

Acute Coronary SyndromeAcute Myocardial Infarction (AMI)Bladder CancerBladder Urothelial CarcinomaCapecitabineColon CancerExtensive Disease Small Cell Lung CancerExtensive Stage Lung Small Cell Cancer

Phase 2

A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

RecruitingNCT06421298

Jinghui WangLung Cancer

Start: 2024-05-17End: 2027-05-30Target: 30Updated: 2024-05-20

Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

RecruitingNCT07061535

Second Affiliated Hospital, Zhejiang University, School of MedicineExtensive Disease Small Cell Lung Cancer, Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer +1

Start: 2025-07-30End: 2027-08-01Target: 40Updated: 2026-09-15

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

RecruitingNCT07717242

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBladder Cancer, Bladder Urothelial Carcinoma

Start: 2026-07-01End: 2029-01-31Target: 80Updated: 2026-07-21

Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer

RecruitingNCT07840677

Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityColon Cancer, Neoadjuvant Immunochemotherapy, PCSK9 Inhibitor

Start: 2026-09-20End: 2029-09-20Target: 70Updated: 2026-09-25

Phase 3

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Not yet recruitingNCT07686796

Guangdong Provincial People's HospitalCapecitabine, Local Advanced Rectal Cancer, Oxaliplatin +4

Start: 2027-01-01End: 2035-01-01Target: 148Updated: 2026-07-07

Phase 4

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

RecruitingNCT06096909

China National Center for Cardiovascular DiseasesAcute Coronary Syndrome, Lipid Lowering, Vascular Inflammation, Non ST Segment Elevation Acute Coronary Syndrome

Start: 2023-11-11End: 2028-06-01Target: 3684Updated: 2026-10-27

Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients

Not yet recruitingNCT06683131

The Affiliated Hospital of Xuzhou Medical UniversityAcute Myocardial Infarction (AMI)

Start: 2025-11-20End: 2027-11-30Target: 1160Updated: 2025-11-21

Unknown Phase

INtensive liPid-lowering Therapy for Acute High-risk IntracRanial or Extracranial atheroSclerosis -II (INSPIRES-2)

Not yet recruitingNCT07341958

Beijing Tiantan HospitalIschemic Stroke or High-risk TIA (ABCD² ≥ 4)

Start: 2026-09-08End: 2027-08-30Target: 242Updated: 2026-10-08

Tafolecimab in Hyperlipidemia: A Study of Different Dosing Intervals

Not yet recruitingNCT07712042

Mei GaoHyperlipidemia